Stereotactic Magnetic Resonance Guided Radiation Therapy

Description

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Conditions

Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)

Stereotactic Magnetic Resonance Guided Radiation Therapy

Condition
Pancreas Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham & Women's Hospital, Boston, Massachusetts, United States, 02115

Boston

Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.
  • * Tumor size ≤ 7cm
  • * Age 18 years of older.
  • * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  • * Ability to understand and the willingness to sign a written informed consent document.
  • * Specific eligibility requirements for each disease site with be covered in each specific cohort.
  • * Specific exclusion requirements for each disease site with be covered in each specific cohort
  • * History of allergic reactions attributed to gadolinium-based IV contrast.
  • * Pregnant women are excluded from this study.
  • * Severe claustrophobia or anxiety
  • * Participants who cannot undergo an MRI

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dana-Farber Cancer Institute,

Jonathan Leeman, MD, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

2028-06